OTCPK:REMI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Remedent's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: REMI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

REMI

-1.4%

US Medical Equipment

1.2%

US Market


1 Year Return

3.3%

REMI

14.9%

US Medical Equipment

16.8%

US Market

Return vs Industry: REMI underperformed the US Medical Equipment industry which returned 15.9% over the past year.

Return vs Market: REMI underperformed the US Market which returned 16.4% over the past year.


Shareholder returns

REMIIndustryMarket
7 Day0%-1.4%1.2%
30 Day-2.5%7.8%4.9%
90 Dayn/a11.7%20.0%
1 Year3.3%3.3%15.9%14.9%19.3%16.8%
3 Year-22.5%-22.5%72.7%68.1%43.7%34.4%
5 Year-48.2%-48.2%116.8%100.0%75.5%56.6%

Price Volatility Vs. Market

How volatile is Remedent's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Remedent undervalued compared to its fair value and its price relative to the market?

0.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: REMI ($0.16) is trading above our estimate of fair value ($0)

Significantly Below Fair Value: REMI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: REMI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: REMI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate REMI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: REMI is good value based on its PB Ratio (0.7x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Remedent forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Remedent has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Remedent performed over the past 5 years?

27.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REMI is currently unprofitable.

Growing Profit Margin: REMI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: REMI is unprofitable, but has reduced losses over the past 5 years at a rate of 27.4% per year.

Accelerating Growth: Unable to compare REMI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: REMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: REMI has a negative Return on Equity (-18.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is Remedent's financial position?


Financial Position Analysis

Short Term Liabilities: REMI's short term assets ($681.1K) do not cover its short term liabilities ($2.9M).

Long Term Liabilities: REMI's short term assets ($681.1K) exceed its long term liabilities ($5.5K).


Debt to Equity History and Analysis

Debt Level: REMI is debt free.

Reducing Debt: REMI has no debt compared to 5 years ago when its debt to equity ratio was 98%.

Debt Coverage: REMI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: REMI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Remedent current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate REMI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REMI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REMI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REMI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REMI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.3yrs

Average management tenure


CEO

Guy De Vreese (65 yo)

11.67yrs

Tenure

Mr. Guy De Vreese serves as Director at Glamsmile (Asia) Limited. Mr. De Vreese has been Chairman of Remedent, Inc. since April 1, 2002 and has been Chief Executive Officer of Remedent NV since December 10 ...


Leadership Team

NamePositionTenureCompensationOwnership
Guy De Vreese
Chairman & CEO11.67yrsno data23.17%
$ 718.2k
Philippe Van Acker
CFO, Chief Accounting Officer & Director11.67yrsUS$192.76kno data
Mark Sernatinger
Executive Officer of United States Office14.33yrsno datano data
Scott Juhl
Executive Officer of United States Office14.33yrsno datano data
Stacey Ammons
Executive Officer of United States Office14.33yrsno datano data

14.3yrs

Average Tenure

Experienced Management: REMI's management team is seasoned and experienced (14.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Guy De Vreese
Chairman & CEO11.67yrsno data23.17%
$ 718.2k
Philippe Van Acker
CFO, Chief Accounting Officer & Director11.67yrsUS$192.76kno data
Fred Kolsteeg
Independent Director18.33yrsUS$117.49k0.48%
$ 14.7k

18.3yrs

Average Tenure

65yo

Average Age

Experienced Board: REMI's board of directors are seasoned and experienced ( 18.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.


Top Shareholders

Company Information

Remedent, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Remedent, Inc.
  • Ticker: REMI
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.099m
  • Shares outstanding: 20.00m
  • Website: https://www.remedent.com

Number of Employees


Location

  • Remedent, Inc.
  • Zuiderlaan 1-3
  • Box 8
  • Gent
  • East Flanders
  • 9000
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REMIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 1998

Biography

Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whiten ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/11 00:02
End of Day Share Price2020/08/06 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.